EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 24 / No 5 (Mai 2008) Med Sci (Paris), 24 5 (2008) 459-462 References
Free Access
Issue
Med Sci (Paris)
Volume 24, Number 5, Mai 2008
Page(s) 459 - 462
Section Nouvelles
DOI https://doi.org/10.1051/medsci/2008245459
Published online 15 May 2008
  1. Verheul HM, Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 2007; 7 : 475–85. [Google Scholar]
  2. Azizi M, Chedid A, Oudard S. Home blood-pressure monitoring in patients receiving sunitinib. N Engl J Med 2008; 358 : 95–7. [Google Scholar]
  3. Fischer C, Jonckx B, Mazzone M, et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007; 131 : 463–75. [Google Scholar]
  4. Luttun, A, Tjwa M, Moons L, et al. 2002. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 2002; 8 : 831–40. [Google Scholar]
  5. Carmeliet P, Moons L, Luttun A, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001; 7 : 575–83. [Google Scholar]
  6. Willett CG, Boucher Y, Duda DG, et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy : continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 2005; 23 : 8136–9. [Google Scholar]
  7. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24 : 16–24. [Google Scholar]
  8. Autiero M, Waltenberger J, Communi D, et al. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 2003; 9 : 936–43. [Google Scholar]
  9. Tammela T, Enholm B, Alitalo K, Paavonen K. The biology of vascular endothelial growth factors. Cardiovasc Res 2005; 65 : 550–63. [Google Scholar]
  10. Kulke MH. Neuroendocrine tumours : clinical presentation and management of localized disease. Cancer Treat Rev 2003; 29 : 363–70. [Google Scholar]
  11. Ratain MJ. Phase II oncology trials : let’s be positive. Clin Cancer Res 2005; 11 : 5661–2. [Google Scholar]
  12. Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 2007; 6 : 734–45. [Google Scholar]
  13. Behar-Cohen F, Sennlaub F, Berdugo M. Espoirs thérapeutiques dans la dégénérescence maculaire liée à l’âge. Med Sci (Paris) 2007; 23 : 127–9. [Google Scholar]
  14. Bramhall SR, Schulz J, Nemunaitis J, et al. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002; 87 : 161–7. [Google Scholar]
  15. Leighl NB, Paz-Ares L, Douillard JY, et al. Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer : National Cancer Institute of Canada-Clinical Trials Group Study BR.18. J Clin Oncol 2005; 23 : 2831–9. [Google Scholar]
  16. Shepherd FA, Giaccone G, Seymour L, et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer : a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002; 20 : 4434–9. [Google Scholar]
  17. Orlando L, Cardillo A, Rocca A, et al. Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer. Anticancer Drugs 2006; 17 : 961–7. [Google Scholar]
  18. Blay JY. Le futur des thérapeutiques ciblées en oncologie, trouver les cibles, traiter tôt et au long cours. Med Sci (Paris) 2008; 23 : 1073–4. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.